Here is some information on Dr Berkson’s work with LDN
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed)
Integr Cancer Ther. 2007 Sep;6(3):293-6.

Reversal of signs and symptoms of a B-cell lymphoma in a patient
using only low-dose naltrexone.

Berkson BM, Rubin DM, Berkson AJ.
Integrative Medical Center of New Mexico, Las Cruces, USA.

PMID: 17761642 [PubMed – indexed for MEDLINE]

integr Cancer Ther. 2006 Mar;5(1):83-9.

The long-term survival of a patient with pancreatic cancer with
metastases to the liver after treatment with the intravenous alpha-
lipoic acid/low-dose naltrexone protocol.

Berkson BM, Rubin DM, Berkson AJ.
Integrative Medical Center of New Mexico and New Mexico State
University, Las Cruces.

The authors describe the long-term survival of a patient with
pancreatic cancer without any toxic adverse effects. The treatment
regimen includes the intravenous alpha-lipoic acid and low-dose
naltrexone (ALA-N) protocol and a healthy lifestyle program. The
patient was told by a reputable university oncology center in October
2002 that there was little hope for his survival. Today, January
2006, however, he is back at work, free from symptoms, and without
appreciable progression of his malignancy. The integrative protocol
described in this article may have the possibility of extending the
life of a patient who would be customarily considered to be terminal.
The authors believe that life scientists will one day develop a cure
for metastatic pancreatic cancer, perhaps via gene therapy or another
biological platform. But until such protocols come to market, the ALA-
N protocol should be studied and considered, given its lack of
toxicity at levels reported. Several other patients are on this
treatment protocol and appear to be doing well at this time.

PMID: 16484716 [PubMed – indexed for MEDLINE]


Leave a Reply